AORT vs GMED

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

AORT

64.2
AI Score
VS
AORT Wins

GMED

53.9
AI Score

Investment Advisor Scores

AORT

64score
Recommendation
BUY

GMED

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AORT GMED Winner
Revenue 242.09M 1.55B GMED
Net Income -12.09M 275.87M GMED
Net Margin -5.0% 17.8% GMED
Operating Income -2.58M 332.82M GMED
ROE -2.7% 5.8% GMED
ROA -1.1% 5.0% GMED
Total Assets 1.07B 5.49B GMED
Cash 77.32M 507.75M GMED
Current Ratio 3.47 4.62 GMED
Free Cash Flow -18.86M 339.32M GMED

Relative Price Performance (Last 90 Days)

AORT 1M: -15.3% · 3M: -9.5% GMED 1M: -6.3% · 3M: -6.1%

Current Technical Phase

AORT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.3%), weak momentum, RSI 34

RSI (14): 33.6 · Price: $22.31

GMED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 45.6 · Price: $75.60

Fundamentals Snapshot

Metric AORT GMED
Market Cap — —
Forward P/E 29.8 14.0
Trailing P/E — 19.2
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.6% 0.7%
Operating Margin 0.1% 0.2%
EPS -0.06 3.88
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, AORT is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.